Angiotensin Receptor Inhibitors for Ischemic Mitral Regurgitation in Coronary Artery Disease

This clinical trial is focused on understanding how a specific type of medication, known as angiotensin receptor/neprilysin inhibitors (ARNI), can help people with a heart condition called ischemic mitral regurgitation (IMR). IMR often occurs in patients who have coronary artery disease, a condition that affects blood flow to the heart. The study is particularly interested in patients who are undergoing a procedure called coronary artery bypass grafting (CABG), which helps improve blood flow to the heart. By exploring how ARNI can aid these patients, the study aims to find better treatment options that could improve heart function and overall health outcomes. Participants in the study will receive the ARNI medication, and researchers will monitor how this treatment impacts their heart condition, specifically looking at changes in their mitral valve function. The medication will be administered alongside their regular treatment plan as they undergo the CABG procedure. The study will carefully measure the outcomes to understand whether ARNI makes a notable difference in managing IMR, which could lead to less invasive and more effective treatment strategies for patients in the future. The study does not specify any risks or benefits, but the goal is to gather data that could lead to enhanced care for those with these heart conditions.